Immunologic response to infection and its role in septic shock

Critical Care Clinics

Volumn 16, Issue 2, 2000, Pages 193-213

  Casey, Larry C ^b  

^a RUSH MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; OXYGEN RADICAL; PEPTIDE HORMONE;

ANTIBODY PRODUCTION; BLOOD CLOTTING; COMPLEMENT ACTIVATION; IMMUNE RESPONSE; INFECTION RISK; MULTIPLE ORGAN FAILURE; PHAGOCYTOSIS; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SYSTEMIC CIRCULATION;

EID: 0034112615     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0749-0704(05)70107-X     Document Type: Article

References (73)

1. E. Abraham A. Anzueto G. Gutierrez Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock Lancet 351 1998 929 933
2. B.J. Appelmelk Y.Q. An B.G. Thijs Recombinant human bactericidal/permeability-increasing protein (rBPI23) is a universal lipopolysaccharide-binding ligand Infect Immun 62 1994 3564 3567
3. W.A. Arden R.R. Fiscus X. Wang Elevations in circulating calcitonin gene-related peptide correlate with hemodynamic deterioration during endotoxin shock in pigs Circ Shock 42 1994 147 153
4. B. Beutler A. Cerami Cachectin: More than a tumor necrosis factor N Engl J Med 316 1987 379 385
5. B. Beutler A. Cerami The biology of cachectin/TNFα primary mediator of the host response Ann Rev Immunol 7 1989 625 655
6. B. Beutler N. Krochin I.W. Milsark Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance Science 232 1976 977 979
7. B. Beutler I.W. Milsark A.C. Cerami Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin Science 229 1985 869 871
8. J.G. Cannon R.G. Tompkins J.A. Gelfand Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever J Infect Dis 161 1990 79 84
9. L.C. Casey R.A. Balk R.C. Bone Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome Ann Intern Med 119 1993 771 778
10. S. Chollet-Martin P. Montravers C. Gilbert High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome Infect Immunol 61 1993 4553 4559
11. De Waal Malefyt R. H. Yssel M. Roncarolo Interleukin 10 Curr Opin Immunol 4 1992 314
12. C. Dinarello Biology of interleukin-1 Chem Immunol 51 1992 1 32
13. C. Dosquet D. Weill J.L. Wautier Cytokines and thrombosis J Cardiovasc Pharmacol 25 suppl 2 1995 s13 s19
14. B. Echtenacher W. Falk D.N. Mannel Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis J Immunol 145 1990 3762 3766
15. J.A. Elias K. Gustilo W. Baeder Synergistic stimulation of fibroblast prostaglandin by recombinant interleukin-1 and tumor necrosis factor J Immunol 138 1987 3812 3816
16. P. Elsbach The bactericidal/permeability-increasing protein (BPI) in antibacterial host defense J Leukoc Biol 64 1998 14 18
17. X.M. Fang S. Schroder A. Hoeft Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis Crit Care Med 27 1999 1330 1334
18. M.J. Fenton D.T. Golenbock LPS-binding proteins and receptors J Leukoc Biol 64 1998 25 32
19. E. Ferrero D. Jiao B.Z. Tsuberi Transgenic mice expressing human CD14 are hypersensitive to lipopolysccharide Immunology 90 1993 2380 2384
20. C. Fisher J.M. Agosti S.M. Opal Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein N Engl J Med 334 1996 1697 1702
21. C. Fisher J.F. Dhainaut S.M. Opal Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome JAMA 271 1994 1835 1843
22. C.J. Fisher G.J. Stolman S.M. Opal Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-labeled, placebo-controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group Crit Care Med 22 1994 12 21
23. G. Friedman S. Jankowski A. Marchant Blood interleukin 10 levels parallel the severity of septic shock J Crit Care 12 1997 183 187
24. T. Ganx Defensins and host defense Science 286 1999 420 421
25. J. Gomez-Jimenez M.C. Martin R. Sauri Interleukin 10 and the monocyte/macrophage-induced inflammatory response in septic shock J Infect Dis 171 1995 472 475
26. Hack C.E. De Groat E.R. R.J. Felt-Bersma Increased plasma levels of interleukin-6 in sepsis Blood 74 1989 1704 1710
27. C.H. Hannum C.J. Wilcox W.P. Arend Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor Nature 343 1990 336 340
28. R. Haworth N. Platt S. Keshav The macrophage scavenger receptor type A is expressed by activated macrophages and protects host against lethal endotoxin shock J Exp Med 186 1997 1431 1439
29. A. Haziot S. Chen E. Ferrero The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage J Immunol 141 1988 547 552
30. A. Haziot E. Ferrero F. Kontgen Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice Immunity 4 1996 407 414
31. A. Haziot E. Ferrero X.Y. Lin CD14-deficient mice are exquisitely insensitive to the effects of LPS Prog Clin Biol Res 392 1995 349 351
32. R.A. Heller K. Song M.A. Onasch Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor Proc Natl Acad Sci USA 87 1990 6151 6155
33. T. Hirano Interleukin-6 and its relation to inflammation and disease Clin Immunol Immunopathol 62 1992 S60 S65
34. W.E. Holmes J. Lee W.J. Kuang Structure and functional expression of a human interleukin-8 receptor Science 253 1991 1278 1280
35. M. Honda S. Yamamoto M. Cheng Human soluble IL-6 receptor: Its detection and enhanced release by HIV infection J Immunol 148 1992 2175 2180
36. M. Howard A. O'Garra H. Ishida Biologic properties of interleukin 10 J Clin Immunol 12 1992 239
37. M. Howard T. Muchamuel S. Andrade Interleukin 10 protects mice from lethal endotoxemia J Exp Med 177 1993 1205 1208
38. T. Iwasaki Y. Uehara L. Graves Herbimycin A blocks IL-1-induced NF-kappa B DNA-binding activity in lymphoid cells lines FEBS Lett 298 1992 240 244
39. C.J. Kirschning H. Wesche Merrill Ayers T. Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide J Exp Med 188 1998 2091 2097
40. M. Kriegler C. Perez K. DeFay A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: Ramifications for the complex physiology of TNF Cell 53 1988 45 53
41. T. Lewis The lives of a cell 1974 Viking Press New York p 92
42. D.N. Mannel D.L. Rosenstreich S.E. Mergenhagen Mechanism of lipopolysaccharide-induced tumor necrosis: Requirement for lipopolysaccharide-sensitive lymphoreticular cells Infect Immunol 24 1979 573 576
43. C. Marty B. Missett F. Tamion Circulating interleukin-8 concentrations in patients with multiple organ failure of septic and non-septic origin Crit Care Med 22 1994 673 679
44. L.T. May U. Santhanam S.B. Tatter Phosphorylation of secreted forms of human beta-2-interferon/hepatocyte stimulating factor/interleukin-6 Biochem Biophys Res Commun 152 1988 1144 1150
45. R. Medzhitov P. Preston-Hurlburt C.A. Janeway A human homologue of the Drosophila Toll protein signals activation of adaptive immunity Nature 388 1997 394 397
46. J.J. Mond A. Lee C.M. Snapper T cell-independent antigens Ann Rev Immunol 13 1995 655 692
47. P.M. Murphy H.L. Tiffany Cloning of complementary DNA encoding a functional human interleukin-8 receptor Science 253 1991 1280 1283
48. M. Muzio G. Natoli S. Sccani The human toll signalling pathway: Divergence of nuclear factor kappa B and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6) J Exp Med 187 1998 2097 2101
49. A. Novogrodasky A. Vanichkin M. Patya Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors Science 264 1994 1319 1322
50. S. Okusaw J.A. Gelfand T. Ikejima Interleukin-1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibitors J Clin Invest 81 1988 1162 1172
51. J.J. Oppheim C.O. Zachariae N. Mukaida Properties of the novel proinflammatory supergene “intercrine” cytokine family Ann Rev Immunol 9 1993 617 648
52. M.K. Pangburn The alternative pathway Ross G.D. Immunobiology of the Complement System 1986 Academic Press Orlando 45 62
53. A. Poltorak X. He I. Smirnova Defective LPS signalling in C3H/HeJ and C5BL/10ScCr mice: Mutations in Tlr4 gene Science 282 1998 2085 2088
54. J.C. Preiser D. Schmartz Van der Linden P. Interleukin-6 administration has no acute hemodynamic or hematologic effect in the dog Cytokine 3 1991 1 4
55. J.L. Rothstein H. Schreiber Synergy between tumor necrosis factor and bacterial products causes hemodynamic necrosis and lethal shock in normal mice Proc Natl Acad Sci USA 85 1988 607 611
56. U.F. Schade Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor Circ Shock 31 1990 11 18
57. L. Shapira S. Takashiba C. Champagne Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-alpha and IL-1 beta production by human monocytes J Immunol 153 1994 1818 1824
58. J.E. Sims R.B. Acres C.E. Grubin Cloning the interleukin 1 receptor from human T cells Proc Natl Acad Sci USA 86 1989 8946 8950
59. F. Stuber M. Petersen F. Bokelmann A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis Crit Care Med 24 1996 381 384
60. L.A. Tartaglia D.V. Goedeel Two TNF receptors Immunol Today 13 1992 151 153
61. S. Tomlinson Complement defense mechanisms Curr Opin Immunol 5 1993 83 89
62. K.J. Tracey Y. Fong D.G. Hesse Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia Nature 330 1987 662 664
63. P.S. Tobias J. Mathison D. Mintz Participation of lipopolysacchride-binding protein in lipopolysaccharide-dependent macrophage activation Am J Resp Cell Mol Biol 7 1992 239 245
64. Van Snick J. Interleukin-6: An overview Annu Rev Immunol 8 1990 253 278
65. Van Zee K.J. T. Kohno E. Fischer Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo Proc Natl Acad Sci USA 89 1992 4845 4849
66. A. Waage A. Halstensen T. Espevik Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease Lancet 1 1987 355 377
67. G. Wakabayaski J.A. Gelfand J.F. Burke A specific receptor antagonist for interleukin-1 prevents Escherichia coli -induced shock in rabbits FASEB J 5 1991 338 343
68. J. Wherry R. Wenzel E. Abraham A controlled randomized double blind clinical trial of monoclonal antibody to human tumor necrosis factor (TNF Mab) in patients with sepsis syndrome Chest 104 1993 48S
69. C.W. White P. Ghezzi C.A. Dinarello Recombinant tumor necrosis factor/cachectin and interleukin-1 pretreatment decreases lung oxidized glutathione accumulation, lung injury, and mortality in rats exposed to hyperoxia J Clin Invest 79 1987 868 873
70. G.G. Wong S.C. Clark Multiple actions of interleukin 6 within a cytokine network Immunol Today 9 1988 137 139
71. M.M. Wurfel B.G. Monks R.R. Ingalls Targeted deletion of the LBP gene leads to profound suppression of LPS responses ex vivo while in vivo responses remain intact J Exp Med 186 1997 2051 2056
72. R.B. Yang M.R. Mark A. Gray Toll-like receptor-2 mediates lipopolysccharide-induced cellular signalling Nature 395 1998 284 288
73. Zee K.J. De Foege L.E. E. Fischer IL-8 in septic shock, endotoxemia, and after IL-1 administration J Immunol 146 1991 3478 3482